FrancophonIA/ELRC3.0 huggingface dataset:
English: The recommended dose for Orbactiv is one single infusion of 1,200 mg administered into a vein over 3 hours.
Croatian: Preporučena doza lijeka Orbactiv je jedna infuzija od 1200 mg primijenjena u venu tijekom 3 sata.
English: Orbactiv may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading.
Croatian: Orbactiv može utjecati na laboratorijske pretrage kojima se određuje stupanj zgrušavanja Vaše krvi i može prouzročiti lažne rezultate.
English: How you will be given Orbactiv 4.
Croatian: Kako ćete dobivati Orbactiv 4. Moguće nuspojave 5. Kako čuvati Orbactiv
English: Keep this medicine out of the sight and reach of children.
Croatian: Kako čuvati Orbactiv Lijek čuvajte izvan pogleda i dohvata djece.
English: • Heart racing or beating fast;
Croatian: • Lupanje srca ili ubrzani otkucaji srca;
English: • Each vial should be swirled gently to avoid foaming and ensure that all of the powder is completely reconstituted in solution.
Croatian: • Svaku bočicu treba nježno okretati kako bi se spriječilo stvaranje pjene i osiguralo da se sav prašak potpuno rekonstituira u otopini.
English: • Flushing of the face and upper body, hives, itching and/or rashes (red man syndrome) • Wheezing;
Croatian: • Naleti crvenila u licu i gornjem dijelu tijela, koprivnjača, svrbež i/ili osip (sindrom crvenog čovjeka);
English: Infusion site reactions, including the following symptoms infusion site phlebitis, infusion site erythema, extravasation, induration, pruritis, rash, oedema peripheral
Croatian: Reakcije na mjestu infuzije, uključujući sljedeće simptome: flebitis na mjestu infuzije, eritem na mjestu infuzije, ekstravazacija, otvrdnuće,
English: Liver function test abnormal (Alanine aminotransferase increased, Aspartate aminotransferase increased)
Croatian: (povišena alanin-aminotransferaza, povišena aspartat-aminotransferaza)
English: • Increased blood bilirubin levels ;
Croatian: • Povišene razine bilirubina u krvi;
English: There were no relevant changes in pharmacokinetics of oritavancin in subjects with moderate hepatic impairment.
Croatian: Nije bilo značajnih promjena u farmakokinetici oritavancina u ispitanika s umjerenim oštećenjem funkcije jetre.
English: • Shortness of breath;
Croatian: • Nedostatak zraka;
English: • Withdraw and discard 120 mL from a 1,000 mL D5W intravenous bag.
Croatian: • Izvucite i bacite 120 ml iz vrećice 5%-tne vodene otopine glukoze za intravensku primjenu od 1000 ml.
English: The primary adverse effect of oritavancin administration to rats and dogs was a dose related accumulation of eosinophilic granules in tissue macrophages including hepatocytes, renal cortical epithelial cells, adrenal cells and macrophages of the reticulo endothelial system.
Croatian: Primarni štetni učinak primjene oritavancina u štakora i pasa bila je nakupljanje eozinofilnih zrnaca povezano s dozom u tkivnim makrofagima, uključujući hepatocite, epitelne stanice bubrežne kore,
English: Oritavancin is a type of antibiotic (a lipoglycopeptide antibiotic) that can kill or stop the growth of certain bacteria.
Croatian: (lipoglikopeptidni antibiotik) koji može ubiti ili zaustaviti rast određenih bakterija.
English: Contains 400 mg oritavancin.
Croatian: Sadrži 400 mg oritavancina
English: Up to 12 hours
Croatian: Do najviše 12 sati
English: Up to 72 hours
Croatian: Do najviše 72 sata
English: • Beta-haemolytic streptococci of Group G
Croatian: • Beta-hemolitički streptokoki skupine G
English: • 40 mL of water for injections (WFI) should be added using a sterile syringe to reconstitute each vial to provide a 10 mg/mL solution per vial.
Croatian: • Sterilnom štrcaljkom potrebno je dodati 40 ml vode za injekcije za rekonstituciju svake bočice kako bi se dobilo 10 mg/ml otopine po bočici.
English: • Itching, skin rash;
Croatian: • Svrbež, osip kože;
English: • To avoid excessive foaming, it is recommended that WFI should be added carefully, along the walls of the vials.
Croatian: • Kako bi se spriječilo prekomjerno stvaranje pjene, vodu za injekcije treba dodavati pažljivo niz stijenke bočica.
English: Your doctor should monitor you in case this happens and treat you as necessary.
Croatian: Vas mora pratiti ako se to dogodi i liječiti u skladu s tim.
English: • Shivering or trembling;
Croatian: • Tresavica ili drhtavica;
English: Adverse reactions for oritavancin from the pooled Phase 3 ABSSSI clinical trials with single dose oritavancin are listed by system organ class in the following table.
Croatian: Nuspojave oritavancina iz udruženih kliničkih ispitivanja akutnih bakterijskih infekcija kože i kožnih struktura faze 3 s jednom dozom oritavancina razvrstane su prema organskim sustavima u sljedećoj tablici.
English: • Peptostreptococcus spp.
Croatian: • Clostridium perfringens • Peptostreptococcus spp.
English: Mannitol Phosphoric acid (for pH-adjustment)
Croatian: 6.1 Popis pomoćnih tvari manitol fosfatna kiselina (za podešavanje pH)
English: After reconstitution, 1 ml of the solution contains 10 mg oritavancin.
Croatian: Nakon rekonstitucije, 1 ml otopine sadrži 10 mg oritavancina.
English: Hypersensitivity (see sections 4.3 and 4.4) , anaphylactic reaction
Croatian: Preosjetljivost (vidjeti dijelove 4.3 i 4.4),
English: • High uric acid levels in the blood;
Croatian: • Niska razina šećera u krvi; • Visoke razine mokraćne kiseline u krvi;
English: After reconstitution and dilution, 1 ml solution for infusion contains 1.2 mg oritavancin.
Croatian: Nakon rekonstitucije i razrjeđivanja, 1 ml otopine za infuziju sadrži 1,2 mg oritavancina
English: These effects result from oritavancin binding to and preventing the action of the phospholipid reagents which activate coagulation in commonly used laboratory coagulation tests.
Croatian: Ti učinci rezultat su oritavancina što se veže za fosfolipidne reagense i sprječava njihovo djelovanje; fosfolipidni reagensi aktiviraju zgrušavanje u uobičajenim laboratorijskim testovima koagulacije.
English: Leucocytoclastic vasculitis, angioedema, erythema multiforme, flushing
Croatian: Leukocitoklastični vaskulitis, angioedem,
English: MIC breakpoints (mg/L)
Croatian: (mg/l)
English: Extramedullary haematopoiesis in the spleen was observed in rats.
Croatian: U štakora je opažena ekstramedularna hematopoeza u slezeni.
English: Reconstitution: Aseptic technique should be used to reconstitute three Orbactiv 400 mg vials.
Croatian: Rekonstitucija: za rekonstituciju tri bočice lijeka Orbactiv od 400 mg treba koristiti aseptičku tehniku.
English: • Headache;
Croatian: • Glavobolja;
English: • Constipation;
Croatian: • Piskanje;
English: Up to 24 hours
Croatian: Do najviše 24 sata
English: The Chromogenic Factor Xa Assay, the Thrombin Time (TT) assay and the assays used for the diagnosis of Heparin Induced Thrombocytopenia (HIT) are not affected by oritavancin.
Croatian: Oritavancin ne utječe na kromogeni test faktora Xa, test trombinskog vremena (TT) i testove korištene za dijagnozu heparinom inducirane trombocitopenije (HIT).
English: - Orbactiv is a powder for concentrate for solution for infusion - Orbactiv is a white to off white powder, supplied in a 50 ml glass vial.
Croatian: Orbactiv je bijeli do gotovo bijeli prašak u staklenoj bočici od 50 ml.
English: Serious hypersensitivity reactions, including anaphylactic reactions and anaphylactic shock have been reported with the use of oritavancin.
Croatian: S primjenom oritavancina prijavljene su ozbiljne reakcije preosjetljivosti, uključujući anafilaktičke reakcije i anafilaktički šok.
English: Biochemistry changes associated with kidney function including decreases in urine-specific gravity and pH and slight increases in blood urea nitrogen and sporadic increases in creatinine were present in both rat and dog after treatment of two weeks.
Croatian: Nakon dvotjednog liječenja, u štakora i u pasa bile su prisutne biokemijske promjene povezane s funkcijom bubrega, uključujući smanjenje specifične težine mokraće i pH vrijednosti te lagano povećanje dušika iz ureje u krvi i sporadičan porast kreatinina.
English: Metabolism and nutrition disorders
Croatian: Poremećaji metabolizma i prehrane Manje često
English: oritavancin 46.6 μg/mL did not affect an assay for activated protein C resistance (APCR), suggesting that there is a low likelihood that oritavancin will interfere with this test.
Croatian: Activated Protein C Resistance, APCR), što ukazuje da postoji mala vjerojatnost da će oritavancin utjecati na taj test.
English: Dilution:
Croatian: Postupak razrjeđivanja:
English: After dilution, 1 ml of the solution for infusion contains 1.2 mg oritavancin.
Croatian: Nakon razrjeđivanja, 1 ml otopine za infuziju sadrži 1,2 mg oritavancina.
English: In Phase 3 ABSSSI clinical trials, more cases of osteomyelitis were reported in the oritavancin-treated arm than in the vancomycin-treated arm (see section 4.8).
Croatian: U kliničkim ispitivanjima liječenja akutnih bakterijskih infekcija kože i kožnih struktura faze 3, prijavljeno je više slučajeva osteomijelitisa u skupni liječenoj oritavancinom nego u skupini liječenoj vankomicinom (vidjeti dio 4.8).
English: Common side effects (may affect up to 1 in 10 patients):
Croatian: Druge se nuspojave pojavljuju sa sljedećom učestalošću: Česte nuspojave (mogu se javiti u manje od 1 na 10 bolesnika):
English: Each vial contains oritavancin diphosphate equivalent to 400 mg oritavancin.
Croatian: Jedna bočica sadrži oritavancindifosfat što odgovara 400 mg oritavancina.
English: - if it is expected that you may need to be given a blood thinning medicine (unfractionated heparin sodium) within 5 days (120 hours) of the dose of Orbactiv.
Croatian: - ako ste alergični na oritavancin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.). - ako se očekuje da će Vam možda trebati dati lijek za razrjeđivanje krvi (nefrakcionirani heparinnatrij) unutar 5 dana (120 sati) od doze lijeka Orbactiv.
English: Dosage adjustment of oritavancin is not needed in patients with mild or moderate renal impairment.
Croatian: Nije potrebna prilagodba doziranja oritavancina u bolesnika s blagim ili umjerenim oštećenjem funkcije bubrega.
English: • Flushing;
Croatian: • Proljev;
English: Sodium chloride solution should not be used for dilution (see section 6.2).
Croatian: Za razrjeđivanje se ne smije koristiti otopina natrijevog klorida (vidjeti dio
English: The reconstituted solution should be further diluted in glucose 5% intravenous infusion bag immediately.
Croatian: Rekonstituiranu otopinu potrebno je odmah dodatno razrijediti u vrećici 5%-tne glukoze za intravensku infuziju.
English: Single-use 50 ml Type 1 glass vials with rubber stoppers and aluminium flip off cap. 3 individual vials are packaged in a carton.
Croatian: Bočice od 50 ml za jednokratnu uporabu (staklo tipa 1) s gumenim čepom i aluminijskim zatvaračem.
English: Histamine-like infusion reactions following immediately or shortly after dosing with oritavancin occurred in both rats and dogs.
Croatian: U štakora i pasa, odmah nakon ili ubrzo nakon doze oritavancina pojavile su se reakcije na infuziju nalik na histaminski odgovor.
English: No dosage adjustment is required for patients with mild to moderate hepatic impairment (Child-Pugh Class B) (see section 5.2).
Croatian: U bolesnika s blagim ili umjerenim oštećenjem funkcije jetre nije potrebno prilagođavati dozu (ChildPugh stadij B) (vidjeti dio 5.2).
English: No effect of oritavancin on the in vivo coagulation system was observed in nonclinical and clinical studies.
Croatian: U kliničkim i nekliničkim ispitivanjima nije zapažen utjecaj oritavancina na in vivo koagulacijski sustav.
English: In mixed infections where other types of bacteria are suspected, your doctor will give you other appropriate antibiotics together with Orbactiv.
Croatian: Vaš liječnik će Vam dati druge prikladne antibiotike uz lijek Orbactiv.
English: Package leaflet: Information for the patient Orbactiv 400 mg powder for concentrate for solution for infusion oritavancin
Croatian: Uputa o lijeku: Informacije za bolesnika Orbactiv 400 mg prašak za koncentrat za otopinu za infuziju oritavancin
English: Activated clotting time (ACT)
Croatian: Aktivirano vrijeme zgrušavanja (AVZ)
English: The pharmacokinetics of oritavancin in patients with severe hepatic impairment has not been studied.
Croatian: Farmakokinetika oritavancina u bolesnika s teškim oštećenjem funkcije jetre nije ispitana.
English: Orbactiv 400 mg powder for concentrate oritavancin
Croatian: Orbactiv 400 mg prašak za koncentrat oritavancin
English: The pharmacokinetics of oritavancin in patients with severe renal impairment has not been evaluated.
Croatian: Farmakokinetika oritavancina u bolesnika s teškim oštećenjem funkcije bubrega nije procijenjena.
English: Dosage adjustment of oritavancin is not needed in patients with mild and moderate hepatic impairment.
Croatian: Nije potrebna prilagodba doziranja oritavancina u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre.
English: Therefore no dose adjustment is required, even if caution should be exercised when prescribing oritavancin to patients with severe hepatic impariment (Child-Pugh Class C).
Croatian: Stoga, iako je potreban oprez pri propisivanju oritavancina bolesnicima s teškim oštećenjem funkcije jetre (Child-Pugh stadij C), nije potrebna prilagodba doze.
English: The pharmacokinetics of oritavancin were evaluated in a study of subjects with moderate hepatic impairment (Child-Pugh Class B, n=20) and compared with healthy subjects (n=20) matched for gender, age and weight.
Croatian: (Child-Pugh stadij B, n= 20) i uspoređena sa zdravim ispitanicima (n= 20) koji su odgovarali po spolu,
English: A study to assess the drug-drug interaction effect of a single 1,200mg dose of oritavancin on the pharmacokinetics of S-warfarin following a single dose was conducted in 36 healthy subjects.
Croatian: U 36 zdravih dobrovoljaca provedeno je ispitivanje radi procjene učinka interakcije između lijekova, jedne doze od 1200 mg oritavancina na farmakokinetiku S-varfarina nakon jedne doze.
English: Silica clot time (SCT)
Croatian: Vrijeme zgrušavanja silicijem (VZS)
English: • Muscle pain;
Croatian: • Bol u mišićima;
English: How to store Orbactiv
Croatian: Ne smijete dobiti Orbactiv
English: Aseptic procedures should be used for the preparation of Orbactiv.
Croatian: Za pripremu lijeka Orbactiv treba primjenjivati aseptičke tehnike.
English: • Reduced blood platelet count below the normal lower limit (known as thrombocytopenia).
Croatian: • Infekcija kosti prouzročena bakterijama (poznata pod nazivom osteomijelitis); • Smanjen broj krvnih pločica ispod donje granice normalnih vrijednosti (poznato pod nazivom trombocitopenija).
English: Frequency of adverse reactions by system organ class
Croatian: Učestalost nuspojava prema klasifikaciji organskih sustava
English: No dosage adjustment is needed in patients with mild or moderate renal impairment (see section 5.2).
Croatian: U bolesnika s blagim ili umjerenim oštećenjem funkcije bubrega nije potrebno prilagođavati dozu (vidjeti dio 5.2).
English: Following a single intravenous infusion in lactating rats, radio-labelled [14C]oritavancin was excreted in milk and absorbed by nursing pups.
Croatian: Nakon jednokratne intravenske infuzije ženkama štakora tijekom laktacije, radioaktivno obilježen
English: Only glucose 5% intravenous bag (D5W) should be used for dilution.
Croatian: Za razrjeđivanje se smije koristiti samo vrećica 5%-tne vodene otopine glukoze za intravensku primjenu.
English: Powder for concentrate for solution for infusion 3 vials
Croatian: Prašak za koncentrat za otopinu za infuziju
English: Antibacterial-associated colitis and pseudomembranous colitis have been reported for oritavancin and may range in severity from mild to life threatening diarrhoea.
Croatian: Kod primjene oritavancina zabilježeni su kolitis i pseudomembranozni kolitis povezani s antibakterijskim djelovanjem, koji mogu poprimiti oblik od blagog proljeva do onog opasnog po život.
English: Orbactiv 400 mg powder for concentrate for solution for infusion
Croatian: Orbactiv 400 mg prašak za koncentrat za otopinu za infuziju
English: patients is 138 (23) μg/ml and 2,800 (28.6) μg•h/mL respectively.
Croatian: Srednja vrijednost (koeficijent varijacije, CV%) maksimalne koncentracije oritavancina (Cmax) i AUC0-∞ u bolesnika koji dobivaju jednokratnu dozu od 1200 mg u bolesnika s akutnom bakterijskom infekcijom kože i kožnih struktura je 138 (23) μg/ml odnosno 2800 (28,6) μg•h/ml.
English: Respiratory, thoracic and mediastinal disorders
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja Manje često
English: • Feeling sick (nausea) or being sick (vomiting);
Croatian: • Mučnina ili povraćanje;
English: Orbactiv 400 mg powder for concentrate for solution for infusion oritavancin
Croatian: Orbactiv 400 mg prašak za koncentrat za otopinu za infuziju oritavancin
English: Orbactiv is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults (see sections 4.4 and 5.1).
Croatian: Orbactiv je indiciran za liječenje akutnih bakterijskih infekcija kože i kožnih struktura u odraslih
English: • Diarrhoea;
Croatian: • Zatvor;
English: Dilution: Three reconstituted vials are needed for dilution for administration of a single 1,200 mg intravenous infusion.
Croatian: Razrjeđivanje: za primjenu jedne intravenske infuzije od 1200 mg potrebno je razrijediti tri rekonstituirane bočice.
English: Abscess
Croatian: Doziranje
English: Susceptibility testing break points
Croatian: Granične vrijednosti ispitivanja osjetljivosti
English: Fertility
Croatian: Tahikardija
English: Further information on Tovanor Breezhaler can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Više informacija o lijeku Tovanor Breezhaler nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: the main measure of effectiveness was improvement in patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second).
Croatian: forsiranog izdisajnog volumena bolesnika (FEV1, maksimalni volumen zraka koji osoba može izdahnuti u sekundi).
English: Tovanor Breezhaler (glycopyrronium bromide) EMA/326862/2018
Croatian: Tovanor Breezhaler (glikopironijev bromid) EMA/326862/2018
English: The most common side effects with Tovanor Breezhaler (seen in more than 1 patient in 100) are dry mouth, nasopharyngitis (inflammation of the nose and throat), insomnia (difficulty sleeping), muscle and bone pain and gastroenteritis (diarrhoea and vomiting).
Croatian: Najčešće nuspojave lijeka Tovanor Breezhaler (zabilježene u više od 1 na 100 bolesnika) jesu suhoća usta, nazofaringitis (upala nosa i grla), insomnija (nesanica), bolovi u mišićima i kostima te gastroenteritis (proljev i povraćanje).
English: After 12 weeks of treatment, Tovanor Breezhaler increased FEV1 by 97 ml more than with placebo in the first study, and by 108 ml more in the second study.
Croatian: U prvom ispitivanju, nakon 12 tjedana terapije lijekom Tovanor Breezhaler FEV1 povećao se za 97 ml više nego uz primjenu placeba, a u drugom ispitivanju za 108 ml više.
English: Side effects reported with Tovanor Breezhaler are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Tovanor Breezhaler pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: This helps to keep the airways open and allows the patient to breathe more easily.
Croatian: To pomaže pri održavanju dišnih putova otvorenima i bolesnicima olakšava disanje.
English: Tovanor Breezhaler capsules, which contain a powder for inhalation, are only used with the Tovanor Breezhaler inhaler and must not be swallowed.
Croatian: Kapsule lijeka Tovanor Breezhaler, koje sadrže prašak inhalata, primjenjuju se samo s inhalatorom za Tovanor Breezhaler i ne smiju se progutati.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tovanor Breezhaler have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Tovanor Breezhaler nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: The European Medicines Agency noted that Tovanor Breezhaler had a modest but relevant benefit for patients in terms of improving lung function, and also improved the symptoms of COPD.
Croatian: Europska agencija za lijekove smatrala je da Tovanor Breezhaler ima skromnu, ali važnu korist za bolesnike jer poboljšava plućnu funkciju te ublažava simptome KOPB-a.
English: Tovanor Breezhaler is a medicine that is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Croatian: Tovanor Breezhaler je lijek koji se primjenjuje za ublažavanje simptoma kronične opstruktivne plućne bolesti (KOPB) u odraslih osoba.
English: In addition, there were no major safety concerns with Tovanor Breezhaler, with side effects similar to other muscarinic receptor antagonist medicines.
Croatian: Osim toga, nisu postojali ozbiljni razlozi za zabrinutost pri primjeni lijeka Tovanor Breezhaler, a nuspojave su slične onima kod drugih antagonista muskarinskih receptora.
English: What measures are being taken to ensure the safe and effective use of Tovanor Breezhaler?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Tovanor Breezhaler?
English: For more information about using Tovanor Breezhaler, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Tovanor Breezhaler pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: As for all medicines, data on the use of Tovanor Breezhaler are continuously monitored.
Croatian: Kao za sve lijekove, podatci o primjeni lijeka Tovanor Breezhaler kontinuirano se prate.
English: An overview of Tovanor Breezhaler and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Tovanor Breezhaler i zašto je odobren u EU-u
English: Therefore, the Agency decided that Tovanor Breezhaler's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Agencija je stoga zaključila da koristi od lijeka Tovanor Breezhaler nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: What is Tovanor Breezhaler and what is it used for?
Croatian: Što je Tovanor Breezhaler i za što se koristi?
English: Tovanor Breezhaler received a marketing authorisation valid throughout the EU on 28 September
Croatian: Lijek Tovanor Breezhaler dobio je odobrenje za stavljanje u promet koje je na snazi u Europskoj uniji od 28. rujna 2012.
English: Tovanor Breezhaler (glycopyrronium bromide)
Croatian: Tovanor Breezhaler (glikopironijev bromid)
English: Other information about Tovanor Breezhaler
Croatian: Ostale informacije o lijeku Tovanor Breezhaler
English: Why is Tovanor Breezhaler authorised in the EU?
Croatian: Zašto je lijek Tovanor Breezhaler odobren u EU-u?
English: Tovanor Breezhaler is used for maintenance (regular) treatment.
Croatian: Tovanor Breezhaler primjenjuje se kao (redovita) terapija održavanja.
English: The active substance in Tovanor Breezhaler, glycopyrronium bromide, is a muscarinic receptor antagonist.
Croatian: Djelatna tvar lijeka Tovanor Breezhaler, glikopironijev bromid, antagonist je muskarinskih receptora.
English: Tovanor Breezhaler can only be obtained with a prescription.
Croatian: Tovanor Breezhaler izdaje se samo na liječnički recept.
English: What are the risks associated with Tovanor Breezhaler?
Croatian: Koji su rizici povezani s lijekom Tovanor Breezhaler?
English: For the full list of all side effects and restrictions with Tovanor Breezhaler, see the package leaflet.
Croatian: Potpuni popis svih nuspojava i ograničenja pri primjeni lijeka Tovanor Breezhaler potražite u uputi o lijeku.
English: Tovanor Breezhaler contains the active substance glycopyrronium bromide.
Croatian: Tovanor Breezhaler sadrži djelatnu tvar glikopironijev bromid.
English: How does Tovanor Breezhaler work?
Croatian: Kako djeluje Tovanor Breezhaler?